ACCESS Newswire·Nov 11, 2026, 11:10 AM ET

Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older

A real-world analysis of 294,499 U.S. Veterans aged 65+ found mNEXSPIKE associated with a 35.9% lower risk of medically attended COVID-19 versus Comirnaty.
The study reported a 47% lower risk of COVID-19-associated hospitalization for mNEXSPIKE recipients compared to Comirnaty users.
An exploratory analysis indicated mNEXSPIKE had a 39.3% relative vaccine effectiveness for hospitalization involving major adverse cardiovascular events (MACE) compared to Comirnaty.
The retrospective study utilized data from the U.S. Veterans Health Administration for participants vaccinated between August 27, 2025, and January 31, 2026.
Moderna funded the study design, data interpretation, manuscript preparation, submission, but did not collect, manage, or analyze the data.
Researchers noted limitations including potential residual confounding, differences in testing behavior, undocumented prior infections, \& limited generalizability due to the predominantly older, male VHA population.
The findings are associative \& do not establish causality, though they provide real-world comparative evidence for vaccine performance in older adults.